A total of three batches of Ezetrol ® (Merck Sharp & Dohme, Haar, Germany) tablets containing 10 mg of ezetimibe were obtained from commercial sources within their shelf-life period, and were identified by Arabic numbers from 1 to 3. HPLCgrade methanol was obtained from Tedia (Fairfield, USA). Ultrapure sodium dodecyl sulfate (SDS electrophoresis) and analytical-grade boric acid were acquired from Bio-Rad Labs (Hercules, CA, USA) and Merck (Darmstadt, Germany), respectively. All chemicals used were of pharmaceutical or special analytical grade. For all of the analyses, ultrapure water was purified using an Elix 3 coupled to a Milli-Q Gradient A10 system (Millipore, Bedford, MA, USA). All solutions were degassed by ultrasonication (Tecnal, São Paulo, Brazil) and filtered through a 0.22-μm Millex filter (Millipore).
Apparatus
CE experiments were performed on an Agilent 3D CE (Agilent Technologies, Waldbronn, Germany) apparatus consisting of an auto sampler, a photodiode array (PDA) detector, a temperature controlling system (4 -60˚C) and power supply able to deliver up to 30 kV. CE ChemStation ® software was used for instrument control, data acquisition and data analysis. The pH of the solutions was measured by a pH meter (Thermo Orion Model 420 A, USA).
The LC method was carried out on a Shimadzu LC system (Shimadzu, Kyoto, Japan) equipped with an SCL-10AVP system controller, an LC-10 ADVP pump, a DGU-14A degasser, an SIL-10ADVP autosampler and an SPD-M10AVP PDA detector. The peak areas were integrated automatically by computer using a Shimadzu Class VP ® V 6.14 software program.
Electrophoretic procedure
At the beginning of each working day, the capillary was conditioned by rinsing with 1 M sodium hydroxide for 10 min, followed by water for 10 min, and then with running electrolyte for 15 min. The electrolyte solution was prepared and filtered daily. To achieve high migration time reproducibility between injections, the capillary was conditioned with 1 M sodium hydroxide (2 min), water (1 min), and a running buffer (5 min). All experiments were carried out on a fused-silica capillary with 50 μm i.d. and 48.5 cm of total length (effective length 40 cm, HP part N˚ G1600-60211), thermostatized at 35˚C, and detected at 232 nm using a PDA detector. Samples were injected using the pressure mode for 5 s at 50 mbar and a constant voltage of 30 kV (current about 32 μA) was applied during the analysis. Since electrolysis can change the electroosmotic flow (EOF) and affect the migration time, efficiency and selectivity, the running electrolyte was replaced with a fresh electrolyte after each three injections. The background electrolyte (BGE) consisted of a mixture of 25 mM aqueous borate buffer and 25 mM anionic detergent SDS (pH 9.75)/methanol (90:10, v/v).
Chromatographic procedure
The validated LC method applied for the analysis of ezetimibe in pharmaceutical dosage forms is described elsewhere. 16 Briefly, the elution was carried out on a reversed-phase Phenomenex (Torrance, USA) Synergi fusion C18 column (150 mm × 4.6 mm i.d., with a particle size of 4 μm and pore size of 80 Å). A security guard holder (4.0 mm × 3.0 mm i.d.) was used to protect the analytical column. The Shimadzu LC system was operated isocratically at 45˚C using a mobile phase of phosphate buffer (0.03 M, pH 4.5)/acetonitrile (35:65, v/v), run at a flow-rate of 0.6 mL/min, and using PDA detection at 234 nm. The injection volume was 20 μL of a solution containing 50 μg/mL for both the reference substance and the samples.
Preparation of reference substance solutions
Stock solutions of ezetimibe and nimesulide were prepared by weighing 20 mg of each reference substance, transferred to individual 10 mL volumetric flasks and diluted to volume with acetonitrile, obtaining a concentration of 2 mg/mL. The stock solutions were stored at 2 -8˚C, protected from light and daily diluted to an appropriate concentration with BGE.
Preparation of sample solutions
To prepare the sample stock solution, tablets containing 10 mg of ezetimibe were accurately weighed and crushed to a fine powder. An appropriated amount was transferred into an individual 50 mL volumetric flask, diluted to volume with acetonitrile, and sonicated for 15 min, obtaining the final concentration of 2 mg/mL of the active pharmaceutical ingredient. This solution was stored at 2 -8˚C, protected from light and daily diluted to an appropriate concentration with BGE.
Validation of the method
The method was validated using samples of pharmaceutical formulations by determinations of the following parameters: specificity, linearity, range, precision, accuracy, limit of detection (LOD), limit of quantitation (LOQ), robustness, and system suitability test, following the ICH guidelines. 17, 18 Nimesulide was used as an internal standard to compensate for any injection errors and minor fluctuations of the migration time, thus improving the reproducibility of the MEKC method.
Specificity is the ability of a method to measure the analyte response in the presence of its potential impurities. 17 The stability-indicating capability of the method was determined by subjecting a reference substance solution (100 μg/mL) to accelerated degradation by acidic, basic, neutral, oxidative, and photolytic conditions to evaluate the interference in the quantitation of ezetimibe. After the procedures, the samples were diluted in BGE to a final concentration of 50 μg/mL. A sample solution prepared in 0.1 M hydrochloric acid was used for acidic hydrolysis, and a sample solution in 0.1 M sodium hydroxide for the basic hydrolysis evaluation. Both solutions were refluxed at 100˚C for 4 h, cooled and neutralized with acid or base, as necessary. For a study under a neutral condition, the samples were diluted in water and heated at 80˚C for 3 h. Oxidative degradation was induced by storing the sample solutions in 5% hydrogen peroxide, at ambient temperature for 24 h, protected from light. Photodegradation was induced by exposing the samples to 200 wh/m 2 of near-ultraviolet light for 24 h. The interference of the excipients of the pharmaceutical formulation was determined by the injection of a sample containing only a placebo (in-house mixture of all the tablet excipients) and a sample containing a placebo added with ezetimibe at a concentration of 50 μg/mL. Then, the specificity of the method was established by determining the peak purity of ezetimibe in the degraded samples using a PDA detector.
The linearity was determined by constructing three calibration curves, each one with seven calibration concentrations of ezetimibe, including the limit of quantitation (LOQ), in the range of 2 -150 μg/mL, prepared in BGE. Three replicates injections of each reference substance solution were made to verify the repeatability of the detector response. The peak area ratio of ezetimibe to IS against the respective standard concentrations was used for plotting a graph, and the linearity was evaluated by a least-squares regression analysis.
The precision of the method was determined by the repeatability and the intermediate precision. The repeatability was examined by six evaluations of the same concentration sample of ezetimibe, on the same day, and under the same 500 ANALYTICAL SCIENCES APRIL 2008, VOL. 24 experimental conditions. The intermediate precision of the method was assessed by carrying out the analysis on three different days (inter-days), and also by other analysts performing the analysis in the same laboratory (betweenanalysts). The accuracy was evaluated by applying the proposed method to the analysis of an in-house mixture of the tablet excipients with known amounts of each drug, to obtain solutions at concentrations of 40, 50, and 60 μg/mL, equivalent to 80, 100, and 120%, of the analytical concentrations, respectively. The accuracy was calculated as the percentage of the drug recovered from the formulation matrix. The LOQ and the limit of detection (LOD) were calculated from the slope and the standard deviation of the intercept of the mean of three calibration curves, determined by a linearregression model, as defined by ICH. The LOQ was also evaluated in an experimental assay.
The robustness was determined by analyzing the same samples under a variety of conditions of the method parameters, such as: buffer pH and concentration, SDS concentration, capillary temperature, voltage applied, and percentage of methanol in the BGE. To assess the stability of ezetimibe, the samples were maintained at 4 -8˚C for 24 h, and also placed into the autosampler at room temperature for 24 h.
For the quantitation of ezetimibe in the dosage forms, 20 tablets of each pharmaceutical sample containing 10 mg of ezetimibe were separated, accurately weighed and crushed to a fine powder. An appropriate amount was transferred into an individual 50 mL volumetric flask, diluted to volume with acetonitrile and sonicated for 15 min, obtaining final concentrations of 2 mg/mL (stock solution). For the analysis, the stock solutions were daily diluted to appropriate concentrations with BGE, injected and the amount of the drug per tablet calculated against the reference substance.
Results and Discussion

Optimization of the electrophoretic conditions
To develop the MEKC method, the influence of different parameters on the migration time, the peak symmetry, and the electric current were optimized. The optimum borate buffer pH, which determines the degree of ionization of the analyte and its electrophoretic mobility, was investigated in the range of 8.0 -11.0. The migration time of ezetimibe increased with an increase of the pH, and pH 9.75 was selected due to a better peak symmetry (about 0.95).
The borate buffer in the concentration range of 15 -35 mM was evaluated, showing a significant effect on the separation performance through its influence on the EOF and the current produced in the capillary. The 25 mM borate buffer was selected for its low current and no significant increase on the migration time. Then, the MEKC was applied and the effect of anionic detergent SDS was assessed in the range of 15 -35 mM, selecting a concentration of 25 mM due to the sharp peaks and an acceptable current achieved. The effects of the organic modifiers acetonitrile or methanol, in the concentration range of 5 -20%, were also evaluated, but no improvement on the electrophoretic conditions was achieved.
The temperature effect on the separation was investigated in the range of 20 -45˚C, showing that an increase of the capillary temperature resulted in a decrease of the migration time and an increase of the current. A temperature of 35˚C was chosen due to the short run time, peak symmetry and acceptable current. The effect of the voltage applied on the separation was studied through changes from 15 to 30 kV, showing that a potential of 30 kV yielded a short analysis time with an acceptable current (about 32 μA).
Method validation
The stability-indicating MEKC method was validated for the analysis of ezetimibe in pharmaceutical dosage forms, with a migration time of about 4.9 min, as shown in the typical electropherogram in Fig. 2 .
The stability-indicating capability of the analytical method is indicated in Fig. 3 , which shows that the acidic and neutral conditions resulted in a significant decrease of the ezetimibe area, without any additional peak (Figs. 3D and 3E) , indicating that the degradation products were not detected by UV. Under the basic condition, a decrease of the area was observed, with one additional peak at 3.82 min (Fig. 3C) . The oxidative condition exhibited no significant decrease of the area (Fig. 3B) . Under the photolytic condition, the ezetimibe content exhibited a significant decrease, and four additional peaks were detected at 3.21, 3.75, 5.15, and 5.25 min (Fig. 3F) . The specificity of the method towards the drug was established through a determination of the purity peak of the analyte and the IS in the working standard solution using a PDA detector. The peak purity was obtained by overlaying the spectra captured at the apex, upslope and downslope using a photodiode array detector. No interference from formulation excipients was found, showing that the peak was free from any coeluting peak, thus demonstrating that the proposed method is specific for the analysis of ezetimibe.
The calibration curves constructed for ezetimibe were found to be linear in the 2 -150 μg/mL range. The value of the calculated determination coefficient (R 2 = 0.9999, y = (0.034665 ± 0.000322)x + (0.025831 ± 0.004720), where, x is concentration and y is the peak area ratio of ezetimibe to IS) indicated the linearity of the calibration curve for the method.
The precision, evaluated as the repeatability of the method, was studied by calculating the relative standard deviation (RSD%) of the migration time and the peak-area ratio for six analyses of the concentration of 50 μg/mL, performed on the same day, under the same experimental conditions. The obtained RSD values were 1.10 and 0.96% for the migration time and the peak-area ratio, respectively.
The intermediate precision was assessed by analyzing two samples of the pharmaceutical formulation on three different days (inter-day, Table 1 ); the RSD values obtained were 0.73 and 0.26%. The between-analysts precision was determined by calculating the RSD for the analysis of two samples of the pharmaceutical formulation by three analysts; the values were found to be 1.15 and 0.86% (Table 2) .
The accuracy was assessed from three replicate determinations of three different solutions containing 40, 50 and 60 μg/mL, 501 ANALYTICAL SCIENCES APRIL 2008, VOL. 24 corresponding to 80, 100 or 120%, of the analytical concentrations, respectively. The absolute means obtained with a mean value of 100.51% and an RSD of 0.54%, are given in Table 3 . It is evident that the method is accurate within the desired range.
For calculating the LOD and LOQ, the calibration equations for ezetimibe were generated by using the mean values of the three independent calibration curves. The obtained values were 0.41 and 1.36 μg/mL, respectively. The LOQ, evaluated experimentally, with a precision lower than 5% and an accuracy within ±5%, was found to be 2.0 μg/mL, suitable as an alternative for the quality-control analysis, also compared to the LC method described with the experimental LOQ of 0.5 μg/mL and the calculated LOD of 0.05 μg/mL. 16 The low sample injection volume and the short optical path-length can be related to the lower sensitivity of the MEKC method.
The results and the experimental range of the selected variables evaluated in the robustness assessment are given in Table 4 , together with the optimized values. There were no significant changes in the MEKC pattern when the modifications were made under the experimental conditions, thus showing the method to be robust. The solutions were also found to be stable during the study period.
A system suitability test was also carried out to evaluate the resolution and the reproducibility of the system for the analysis to be performed, using five replicate injections of a reference substance solution containing 50 μg/mL of ezetimibe. The results given in Table 5 show that the parameters evaluated are within a suitable range.
Method application
The MEKC method validated in this paper was applied in parallel with the LC method for the determination of ezetimibe in the same batches of pharmaceutical dosage forms, demonstrating mean values 0.66% lower for the MEKC, as 502 ANALYTICAL SCIENCES APRIL 2008, VOL. 24 shown in the Table 6 . The experimental values were also compared statistically by the Student's t-test showing a nonsignificant difference (P > 0.05) for the precision and the accuracy. The proposed method can be useful in the determination of ezetimibe without prior separation of the excipients of the formulation, with the advantages of small sample volumes, low consumption of reagents, organic solvents and higher peak efficiencies.
Conclusion
The results of validation studies show that the MEKC method is sensitive with an LOQ of 2 μg/mL, accurate with a mean value of 100.51%, economic, specific and stability-indicating. It possesses significant linearity (R 2 = 0.9999) and a precision of the peak area ratio with an RSD of 0.96%, without any interference from the excipients. Therefore, the proposed method was successfully applied as an alternative tool for the quantitative analysis of ezetimibe in pharmaceutical dosage forms, representing an improvement for the quality control, and also contributing to assure the therapeutic efficacy of the drug. 
